Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)

The article “Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)” published in the journal Clinical Pharmacology & Therapeutics (CPT) by the American Society for Clinical Pharmacology and Therapeutics (ASCPT) provides a comprehensive framework for understanding and modeling drug disposition in patients with NAFLD. It highlights the importance of using IVIVE-PBPK/PD and QSP/QST modeling to predict pharmacokinetic and pharmacodynamic outcomes, addressing the complexities of polypharmacy and comorbidities in this population. The study underscores the need for reliable system and drug data to build virtual populations and improve pharmacotherapy for NAFLD patients.